Vaccines

Journal Browser

► Journal Browser

Special Issue Editors

Prof. Dr. Wangxue Chen

E-Mail Website
Guest Editor

Human Health and Therapeutics Research Center (HHT), National Research Council Canada, Ottawa, ON, Canada
Interests: antimicrobial resistance; phage therapy; host–pathogen interaction; vaccines; alternatives to antibiotics
Special Issues, Collections and Topics in MDPI journals

Dr. Xuguang Li

E-Mail Website
Guest Editor

Centre for Biologics Evaluation, Biologics and Radiopharmaceutical Drug Directorate, Health Products and Food Branch (HPFB), Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada
Interests: immunity

Prof. Dr. Amine A. Kamen

E-Mail Website
Guest Editor

Department of Bioengineering, McGill University, Montreal, QC H2X 1Y4, Canada
Interests: cell culture engineering; bioprocess optimization and scale-up; process analytical technologies and process control; viral vaccines manufacturing; viral vectors and nanoparticules for gene delivery and vaccination
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Vaccines are one of the most effective medical inventions in modern history and have saved hundreds of millions of lives so far. The rapid development and deployment of vaccines in response to the COVID-19 pandemic have showcased the unprecedented success of vaccines in global public health, security, and prosperity. Vaccination is highly cost-effective in preventing microbial infection and halting its transmission, and also plays a critical role in the efforts to reduce antimicrobial use.

The tremendous global political enthusiasm, research efforts, and financial investment in vaccine development during the COVID-19 pandemic response lead to significant advances in many aspects of vaccine R&D, including novel vaccine platforms and technologies, the rapid development and production of vaccines, and the renewed recognition of the importance of mucosal immunity and vaccination. These advances are likely to accelerate vaccine development and production for future responses to pandemics and emerging infections.

This Special Issue aims to provide a platform for sharing the most recent advances in the development of novel vaccine candidates, platforms, and technologies for combating emerging infections and future pandemics. More specifically, we welcome the contribution of original research articles, reviews, and commentaries that address the following topics:

New vaccine platforms, technologies, and adjuvants;
Universal vaccine candidates;
Mucosal vaccines and vaccination;
Modular vaccine platforms for rapid biomanufacturing and expedited regulatory approval;
Vaccines as a tool for antimicrobial resistance;
AI application in the rapid identification of novel vaccine antigens;
Immune correlates of vaccine-induced protection;
Systems immunology and vaccinology;
Novel in vitro and in vivoassays and models for assessing vaccine-induced immunity and predicting vaccine efficacies;
Vaccine bioprocess and manufactures.

Prof. Dr. Wangxue Chen
Dr. Xuguang Li
Prof. Dr. Amine A. Kamen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

novel vaccines and adjuvant
universal vaccines
mucosal vaccines
emerging infections
antimicrobial resistance
systems vaccinology
vaccine production

Published Papers (1 paper)

Research

15 pages, 4547 KiB

Open AccessArticle

Optimization of Culture Media and Feeding Strategy for High Titer Production of an Adenoviral Vector in HEK 293 Fed-Batch Culture

by Chun Fang Shen, Anja Rodenbrock, Stephane Lanthier, Elodie Burney and Martin Loignon

Vaccines 2024, 12(5), 524; https://doi.org/10.3390/vaccines12050524 - 10 May 2024

Viewed by 240

Abstract

Adenoviruses are efficient and safe vectors for delivering target antigens and adenovirus-based vaccines have been used against a wide variety of pathogens, including tuberculosis and COVID-19. Cost-effective and scalable biomanufacturing processes are critical for the commercialization of adenovirus-vectored vaccines. Adenoviral vectors are commonly produced through the infection of batch cultures at low cell density cultures, mostly because infections at high cell densities result in reduced cell-specific virus productivity and does not improve volumetric productivity. In this study, we have investigated the feasibility of improving the volumetric productivity by infecting fed-batch cultures at high cell densities. Four commercial and one in-house developed serum-free media were first tested for supporting growth of HEK 293 cells and production of adenovirus type 5 (Ad5) in batch culture. Two best media were then selected for development of fed-batch culture to improve cell growth and virus productivity. A maximum viable cell density up to 16 × 10⁶ cells/mL was achieved in shake flask fed-batch cultures using the selected media and commercial or in-house developed feeds. The volumetric virus productivity was improved by up to six folds, reaching 3.0 × 10¹⁰ total viral particles/mL in the fed-batch culture cultivated with the media and feeds developed in house and infected at a cell density of 5 × 10⁶ cells/mL. Additional rounds of optimization of media and feed were required to maintain the improved titer when the fed-batch culture was scaled up in a bench scale (3 L) bioreactor. Overall, the results suggested that fed-batch culture is a simple and feasible process to significantly improve the volumetric productivity of Ad5 through optimization and balance of nutrients in culture media and feeds. Full article

(This article belongs to the Special Issue Novel Vaccines and Vaccine Technologies for Emerging Infections)

► Show Figures